Scilex Holding Co Stock Price, News & Analysis

Scilex Holding Company (Nasdaq: SCLX) has announced a $50 million registered convertible financing to refinance and restructure existing debt, strengthening its financial profile. The offering involves affiliates of Murchinson, 3i LP, and Oramed Pharmaceuticals, Inc., and is expected to close on October 7, 2024. Key points include:

1. Issuance of new tranche B senior secured convertible notes and warrants.
2. Exchange and reduction of $22.5 million principal balance under the existing Oramed Note.
3. Retirement of the revolving facility with eCapital Healthcare Corp.
4. Over the past 12 months, Scilex has addressed and restructured debt with payments exceeding $80 million.
5. The financing aims to position Scilex for sustainable, long-term growth in its plan to become a leading non-opioid pain management company.

Scilex Holding Company (Nasdaq: SCLX) announced that the U.S. Bankruptcy Court for the Southern District of Texas has extended the lock-up period on Scilex Dividend Stock, previously distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ) to its stockholders, to January 31, 2025. This extension applies only to the Dividend Stock and not to other Scilex securities. The lock-up was previously set to expire on September 30, 2024. As a result, shares of the Dividend Stock, including those held by brokerage firms, cannot be sold, transferred, or disposed of until the new expiration date. Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of this extension.

Scilex Holding Company (NASDAQ: SCLX) has announced continued support from Endeavor Distribution for its commercial products and the satisfaction of a $10 million loan from FSF 33433 Key points:

• Scilex and Endeavor entered a multi-year distribution agreement in June 2024
• $14 million of products shipped to Endeavor, with a pending $10 million order for Q4 2024
• The FSF loan will be satisfied through delivery of ZTlido product
• Partnership aims to expand access to Scilex's non-opioid pain management products (ZTlido®, ELYXYB®, and GLOPERBA®) across the U.S.
• Targeting thousands of pharmacies and extended care outlets nationally

This agreement is expected to strengthen Scilex's market presence and broaden patient access to its non-opioid pain management solutions.

Scilex Holding Company (Nasdaq: SCLX), a revenue-generating company focused on non-opioid pain management products, has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®). This accreditation confirms that Scilex has met all the drug distributor criteria established by NABP, a nonprofit organization founded in 1904 that works with state pharmacy boards to support patient and prescription drug safety.

NABP's activities include conducting examinations to assess pharmacist competency, facilitating pharmacist licensure transfer, providing verification services, and overseeing various pharmacy accreditation programs. This accreditation is a significant milestone for Scilex, potentially enhancing its credibility in the pharmaceutical distribution sector.

Scilex Holding Company (Nasdaq: SCLX), a revenue-generating company focused on non-opioid pain management products, has announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York City.

Jaisim Shah, CEO and President of Scilex, will present on September 11, 2024, from 8-8:30am ET at the Lotte NY Palace Hotel. This presentation offers an opportunity for investors to gain insights into Scilex's innovative approach to acute and chronic pain treatment.

Scilex's portfolio includes notable products such as ZTlido®, ELYXYB®, and Gloperba®. The company's focus on acquiring, developing, and commercializing non-opioid pain management solutions positions it as a significant player in the pharmaceutical industry.

Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, announced the acceptance of a presentation at the 2024 American College of Rheumatology Convergence conference. The presentation, titled 'Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model', will be held on November 16, 2024.

The presentation will focus on GLOPERBA®, the first liquid formulation of colchicine, which offers precision dosing for at-risk gout patients. Scilex recently received FDA approval for an updated GLOPERBA® label, allowing for dosage adjustments in various clinical situations, including a reduced daily dose for patients with severe renal impairment.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company (SCLX), has signed a merger agreement with Denali Capital Acquisition Corp (DECA) for a proposed business combination. The deal values Semnur at $2.5 billion pre-transaction. This merger aims to create a publicly traded biopharma company, focusing on Semnur's non-opioid product SP-102 (SEMDEXA™), a Phase 3 novel gel for treating sciatica.

Key points:

• SP-102 has FDA Fast Track status and projected annual sales of $1.5-$2.0 billion by the 5th year of launch
• The merger is expected to close by Q1 2025
• Scilex will remain the majority shareholder of the combined company
• The combined company will be renamed Semnur Pharmaceuticals, Inc. and listed on Nasdaq as 'SMNR'

Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, will present research on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV, September 3-5, 2024. Key highlights include:

1. A non-CME presentation by Dr. Charles Argoff on September 4, discussing pain relief options when gabapentinoids are insufficient.

2. Two presentations by Dr. Srinivas Nalamachu on September 5, comparing Lidocaine Topical System 1.8% to Lidocaine 5% Patch, focusing on decreased opioid utilization and cost effectiveness.

These presentations aim to showcase ZTlido's potential in addressing unmet needs in pain management, particularly for patients with neuropathic pain conditions like PHN.

Scilex Holding Company (Nasdaq: SCLX) announced FDA approval for label updates to GLOPERBA®, the first and only liquid oral version of colchicine for gout flare prophylaxis in adults. This approval allows for precision dosing, particularly beneficial for the 70% of gout patients with chronic kidney disease or gastrointestinal sensitivity who may require lower doses than the standard 0.6 mg tablet.

GLOPERBA® enables dosage reduction to 0.3 mg/day for patients with severe renal impairment. The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028. A recent market study showed high interest among rheumatologists in GLOPERBA® for at-risk patient populations needing lower precision dosing to mitigate colchicine toxicity risk.